Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
By A. Drilon, T. Laetsch, S. Kummar, S. DuBois, U. Lassen, G. Demetri, M. Nathenson, R. Doebele, A. Farago, A. Pappo and 28 more. New England Journal of Medicine, 2018
2,224 citations recorded by the source corpus.
Background Fusions involving one of three tropomyosin receptor kinases (TRK) occur in diverse cancers in children and adults. We evaluated the efficacy and safety of larotrectinib, a highly selective TRK inhibitor, in adults and children who had tumors with these fusions. Methods We enrolled patients with consecutively and prospectively identified TRK fusion–positive cancers, detected by molecular profiling as routinely performed at each site, into one of three protocols: a phase 1 study involving adults, a phase 1–2 study involving children, or a phase 2 study involving adolescents and adults. The primary end point for the combined analysis was the overall response rate according to independent review. Secondary end points included duration of response, progression‐free survival, and safety. Results A total of 55 patients, ranging in age from 4 months to 76 years, were enrolled and treated. Patients had 17 unique TRK fusion–positive tumor types. The overall response rate was 75% (95% confidence interval [CI], 61 to 85) according to independent review and 80% (95% CI, 67 to 90) according to investigator assessment. At 1 year, 71% of the responses were ongoing and 55% of the patients remained progression‐free. The median duration of response and progression‐free survival had not been reached. At a median follow‐up of 9.4 months, 86% of the patients with a response (38 of 44 patients) were continuing treatment or had undergone surgery that was intended to be curative. Adverse events were predominantly of grade 1, and no adverse event of grade 3 or 4 that was considered by the investigators to be related to larotrectinib occurred in more than 5% of patients. No patient discontinued larotrectinib owing to drug‐related adverse events. Conclusions Larotrectinib had marked and durable antitumor activity in patients with TRK fusion–positive cancer, regardless of the age of the patient or of the tumor type. (Funded by Loxo Oncology and others; ClinicalTrials.gov numbers, NCT02122913, NCT02637687, and NCT02576431.)
Subfields: Gastroenterology, Molecular Biology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/5bdfabb8fd4dd38357a24f24cf03da3bf40660c1
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
- J. Reis-Filho
- Abel Gonzalez-Perez
- Núria López-Bigas
- Funda Meric-Bernstam
- Nikolaus Schultz
- Charles Swanton
- Sohrab P. Shah
- G. Tortora
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group. (2020, background): “According to basket trials, patients with MSI-H and NTRK fusion-positive tumours treated with ICIs and TRK inhibitors are expected to provide benefit.(48,73) Some limited responses were observed in patients with EGFR- and METamplified metastatic gastric cancer (mGC) treated with cetuximab and crizot”
- Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2019, background): “Partial responses were observed in all five TC patients treated with this drug in a recently reported phase I/II trial [112].”
- Accurate and efficient detection of gene fusions from RNA sequencing data (2021, background): “For example, we identified a fusion with NTRK1, which retained the kinase domain of NTRK1, but instead of the more common fusion partner TPM3 (Drilon et al. 2018), the gene CEL served as 5′ fusion partner.”